Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down – Here’s What Happened

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) shares gapped down before the market opened on Monday . The stock had previously closed at $10.54, but opened at $9.38. Lexeo Therapeutics shares last traded at $7.6610, with a volume of 706,605 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LXEO. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Raymond James Financial began coverage on shares of Lexeo Therapeutics in a report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price target for the company. Guggenheim started coverage on shares of Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price on the stock. Cantor Fitzgerald assumed coverage on Lexeo Therapeutics in a research note on Monday, December 1st. They issued an “overweight” rating and a $19.00 target price for the company. Finally, Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lexeo Therapeutics has an average rating of “Moderate Buy” and an average target price of $19.33.

Lexeo Therapeutics Trading Down 23.8%

The stock has a market cap of $586.52 million, a P/E ratio of -2.98 and a beta of 1.75. The stock’s 50-day moving average is $9.49 and its 200-day moving average is $7.07.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. On average, equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Tai Sandi See sold 3,888 shares of the company’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the sale, the insider directly owned 65,862 shares of the company’s stock, valued at approximately $588,806.28. This represents a 5.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Adler sold 3,382 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the transaction, the insider owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This trade represents a 4.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 24,646 shares of company stock valued at $221,037. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Lexeo Therapeutics during the second quarter worth $60,000. Savant Capital LLC purchased a new position in Lexeo Therapeutics in the second quarter valued at about $119,000. Ethic Inc. acquired a new position in Lexeo Therapeutics in the 2nd quarter worth about $44,000. Palumbo Wealth Management LLC purchased a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth about $226,000. Finally, Affinity Asset Advisors LLC raised its stake in shares of Lexeo Therapeutics by 142.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock worth $14,429,000 after purchasing an additional 2,108,474 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.